A new prediction tool may help identify which people with ANCA-associated vasculitis (AAV) are at risk of developing venous thromboembolism (VTE), a condition in which blood clots block blood flow through veins, a study showed. Using real-world patient data, researchers developed the AAV-VTE model based on four factors that…
New model may help identify which AAV patients are at risk of blood clots
ANCA-associated vasculitis (AAV), marked by inflammation and damage to small blood vessels in the body, still shows low-level immune activity in the background even when symptoms are absent, a study found. This is particularly true for its rare type EGPA, fully, eosinophilic granulomatosis with polyangiitis, according to the…
If you live with ANCA vasculitis, you’ve probably heard the word “acceptance” more than once. It’s a word that can feel loaded and even frustrating. When people suggest acceptance, it can sound like they’re asking us to like what has happened, to stop fighting, or to quietly surrender to…
ANCA-associated vasculitis (AAV) patients with kidney failure requiring long-term dialysis have survival rates comparable to those of people with kidney failure due to other causes, according to a registry-based study in China. Among the 54 AAV patients identified in the dialysis registry, death was mainly due to infections, and none…
Nkarta said it expects initial data from a clinical trial testing its cell therapy candidate NKX019 in adults with ANCA-associated vasculitis (AAV) and other autoimmune diseases to be presented later this year. The Phase 1/2 Ntrust-2 trial (NCT06733935) is testing several doses of NKX019 in up to…
In our ANCA vasculitis community, the real F-word is fatigue. And I need to say something about it plainly: What we experience is definitely not the tiredness that healthy people know. Fatigue in vasculitis is not just sleepiness. It is not the grogginess after a bad night’s sleep…
People with ANCA-associated vasculitis (AAV) are more likely to have worse kidney function and related outcomes if their self-targeting antibodies, called ANCAs, activate immune cells via the Fc gamma receptor protein, a study suggested. “[Fc gamma-driven] ANCA can be a biomarker for poor kidney prognosis in ANCA-associated vasculitis,” the…
Adding plasma exchange, a blood-cleaning procedure, to standard therapy to induce disease remission may help reduce short-term mortality in people with ANCA-associated vasculitis (AAV) with poor kidney function, a study in China shows. Still, mortality rates at one year were comparable between patients who received plasma exchange and those…
In the world of rare disease and chronic illness advocacy, certain phrases catch on quickly. They appear in research papers, nonprofit materials, conference presentations, and patient engagement efforts. One phrase I hear constantly is “lived experience.” To be honest, I’ve never liked it. This may sound like a small thing.
In most people with kidney damage due to ANCA-associated vasculitis (AAV), outcomes from initial treatment to bring the disease under control are similar across commonly used immunosuppressive therapies, including cyclophosphamide and rituximab. That’s according to a study analyzing data from hundreds of patients at several European centers.
Recent Posts
- Using the spoon theory to manage my energy with chronic illness
- FDA proposes removing Tavneos from market over data concerns
- Testing iron protein in blood may improve AAV monitoring and care
- Even with ANCA vasculitis, we can be awe-struck by our own bodies
- Current adult AAV criteria better at classifying the disease in children